NextGen Healthcare Reports Fiscal 2022 Fourth Quarter and Full Year Results

5/17/2022

达到侦察rd Bookings in the Fiscal 2022 Fourth Quarter

ATLANTA--(BUSINESS WIRE)--May 17, 2022-- NextGen Healthcare, Inc.(Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal fourth quarter and year ended March 31, 2022.

Fiscal 2022 Fourth Quarter and Full Year Highlights

  • Total revenue for the fiscal 2022 fourth quarter was $151.3 millioncompared to $144.2 millionfor the same period a year ago, or 5% growth. Revenue for the fiscal year ended March 31, 2022was $596.4 millioncompared to $556.8 milliona year ago.
  • 经常性收入亚柯unted for 91% of total revenue in the fiscal 2022 fourth quarter, or $137.2 million, growing 6% over the year ago period.
  • Subscription services revenue in the fiscal 2022 fourth quarter generated $42.1 million, or 10% growth over the prior year period, driven by demand for surround solutions.
  • Fiscal 2022 fourth quarter bookings, which reflects annual contract value, was $41.4 million, a recent record for the company, and reflects growth of 18% over fiscal 2021 fourth quarter.
  • Fully diluted net income per share in the fiscal 2022 fourth quarter was $0.01compared to net loss of $0.01per share the same period a year ago. Fully diluted net income per share for fiscal year 2022 was $0.02compared to $0.14per share a year ago.
  • On a non-GAAP basis, fully diluted earnings per share for the fiscal 2022 fourth quarter was $0.19compared to $0.21for the same period a year ago. On a non-GAAP basis, fully diluted earnings per share for fiscal year 2022 was $0.98compared to $0.98reported a year ago.

“Fiscal fourth quarter reflects another strong performance driven by broad demand for our solutions and the high level of execution by our team. To better position us for faster revenue growth and operating leverage, we have accelerated the pace of investments in strategic domains – Enterprise, Office and Insights,” said David Sides, President and Chief Executive Officer of 188金宝搏手机app . “We are dedicated to our mission of advancing ambulatory care with innovations for healthier communities and at our recent investor event, we provided a view into our exciting future. The company is on a clear path to demonstrate accelerating revenue growth, and we look forward to providing updates as the year progresses.”

188金宝搏手机app confirms its fiscal year 2023 revenue and non-GAAP earnings per share guidance and introduces an adjusted EBITDA range for the same period. The Company’s fiscal year 2023 financial guidance is as follows:

  • Revenue of between $628 millionand $640 million
  • Adjusted EBITDA of between $111 millionand $116 million
  • Non-GAAP earnings per share of between $0.95and $1.01

Conference Call Information

188金宝搏手机app will host a conference call today at 5:00 p.m. ESTto discuss operating results from its fiscal 2022 fourth quarter and year ended March 31, 2022. Shareholders and interested participants may listen to a live broadcast of the call by dialing 866-831-8713 or 203-518-9822 for international callers and referencing participant code NXGNQ422 approximately 15 minutes prior to the call. A recording of the live webcast will be available oninvestor.www.orderpulsa.comafter the call. It will be archived for 90 days.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements we make regarding our fiscal year 2023 outlook, financial and operating results, strategic priorities, growth initiatives and expected capital expenditures. These forward-looking statements are based on the current beliefs, expectations, and assumptions of the Company's management relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). The words “positioned,” “proposed,” “potential,” “project,” “expect,” “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “estimate, “strategy,” “expectations,” “future,” “likely,” “may,” “should,” “will,” variations thereof or similar expressions are intended to identify such forward-looking statements.

Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements, including but not limited to: changes in laws and regulations applicable to our business; changes in market conditions and receptivity to our services and offerings; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; our ability to maintain and expand our business with existing clients or effectively transition clients to newer products; our ability to attract new partners and successfully capture new opportunities; our ability to develop and grow partner relationships; our ability to attract and retain key employees; our ability to anticipate or respond quickly to market changes, execute our strategy and manage growth; the impact of litigation and governmental and regulatory agency investigations; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; the impact of the COVID-19 pandemic on our operations and demand for our services; impact of breaches or failures of the Company’s information security measures or unauthorized access to a customer’s data; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions. Additional discussion of these and other risks, uncertainties and factors affecting our business is contained in our filings with the SEC, including our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q.

A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S.公认会计准则。根据监管要求的G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP.

The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, impairment of assets, restructuring costs, shareholder disputes and related costs, net of insurance, which include net securities litigation defense, proxy contest, and related costs, share-based compensation, and other non-run-rate expenses from GAAP income before provision for income taxes.

公司利用规范化税老鼠e to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each quarter of fiscal year 2022 was 20.0%. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

The Company calculates free cash flow as total net cash provided by operating activities, net of cash used for the additions of capitalized software costs and equipment and improvements. The Company calculates net debt as line of credit less cash and cash equivalents. The Company calculates non-GAAP adjusted EBITDA by excluding net acquisition costs, amortization of acquired intangible assets, impairment of assets, restructuring costs, shareholder disputes and related costs, net of insurance, which include net securities litigation defense, proxy contest, and related costs, share-based compensation, and other non-run-rate expenses from GAAP income from operations and then adding back amortization of capitalized software costs and depreciation as presented within the condensed consolidated statements of cash flows. Non-GAAP adjusted EBITDA margin is calculated as non-GAAP adjusted EBITDA divided by total revenues. The Company calculates Rule of 40 as annual revenue growth rate plus non-GAAP adjusted EBITDA margin.

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, impairment of assets, restructuring costs, shareholder disputes and related costs, which include net securities litigation defense, proxy contest, and related costs, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc.(Nasdaq: NXGN) is a leading provider of innovative technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and dental providers in their journey toward whole person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all. Learn more atwww.orderpulsa.com, and follow us onFacebook,Twitter,LinkedIn,YouTubeandInstagram.

NEXTGEN HEALTHCARE, INC.

浓缩的收入合并报表

(In thousands, except per share data)

(Unaudited)

Three Months

Ended March 31,

Fiscal Year

Ended March 31,

2022

2021

2022

2021

Revenues:

Recurring

$

137,227

$

129,363

$

539,713

$

502,819

Software, hardware, and other non-recurring

14,032

14,825

56,637

54,002

Total revenues

151,259

144,188

596,350

556,821

Cost of revenue:

Recurring

60,169

54,660

232,481

212,199

Software, hardware, and other non-recurring

7,949

7,533

31,034

26,457

Amortization of capitalized software costs and acquired intangible assets

7,643

7,588

31,889

36,768

Total cost of revenue

75,761

69,781

295,404

275,424

Gross profit

75,498

74,407

300,946

281,397

Operating expenses:

Selling, general and administrative

50,046

48,870

209,661

180,529

Research and development costs, net

19,428

21,390

76,657

75,501

Amortization of acquired intangible assets

882

1,113

3,525

4,449

Impairment of assets

2,329

3,324

3,906

5,539

Restructuring costs

—

—

539

2,562

Total operating expenses

72,685

74,697

294,288

268,580

Income (loss) from operations

2,813

(290

)

6,658

12,817

Interest income

22

11

101

38

Interest expense

(541

)

(643

)

(1,499

)

(3,516

)

Other expense, net

(21

)

(47

)

(64

)

(64

)

Income (loss) before provision for (benefit of) income taxes

2,273

(969

)

5,196

9,275

Provision for (benefit of) income taxes

1,925

(389

)

3,578

(240

)

Net income (loss):

$

348

$

(580

)

$

1,618

$

9,515

Net income (loss) per share:

Basic

$

0.01

$

(0.01

)

$

0.02

$

0.14

Diluted

$

0.01

$

(0.01

)

$

0.02

$

0.14

Weighted-average shares outstanding:

Basic

66,929

67,029

67,370

66,739

Diluted

67,547

67,919

67,788

66,885

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

March 31, 2022

March 31, 2021

ASSETS

Current assets:

Cash and cash equivalents

$

59,829

$

73,295

Restricted cash and cash equivalents

6,918

5,280

Accounts receivable, net

76,057

77,541

Contract assets

25,157

19,481

Income taxes receivable

6,507

765

Prepaid expenses and other current assets

37,102

31,282

Total current assets

211,570

207,644

Equipment and improvements, net

9,120

14,539

Capitalized software costs, net

43,958

41,474

Operating lease assets

11,316

18,446

Deferred income taxes, net

19,259

19,474

Contract assets, net of current

1,910

1,976

Intangibles, net

24,303

36,700

Goodwill

267,212

267,212

Other assets

39,026

37,021

Total assets

$

627,674

$

644,486

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable

$

9,125

$

11,378

Contract liabilities

61,280

52,863

Accrued compensation and related benefits

48,736

50,374

Income taxes payable

99

584

Operating lease liabilities

8,089

12,735

Other current liabilities

53,533

52,699

Total current liabilities

180,862

180,633

Deferred compensation

7,230

6,620

Operating lease liabilities, net of current

11,934

18,453

Other noncurrent liabilities

4,570

7,136

Total liabilities

204,596

212,842

Commitments and contingencies

Shareholders' equity:

Common stock, $0.01par value; authorized 100,000 shares; 69,245 and 67,069 shares issued at March 31, 2022and March 31, 2021, respectively; 67,075 and 67,069 shares outstanding at March 31, 2022and March 31, 2021, respectively

692

671

Treasurystock, at cost, 2,170 shares at March 31, 2022

(35,874

)

—

除了al paid-in capital

329,917

304,263

积累其他综合损失

(1,909

)

(1,924

)

Retained earnings

130,252

128,634

Total shareholders' equity

423,078

431,644

Total liabilities and shareholders' equity

$

627,674

$

644,486

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Three Months
Ended March 31,

Fiscal Year
Ended March 31,

2022

2021

2022

2021

Cash flows from operating activities:

Net income (loss)

$

348

$

(580

)

$

1,618

$

9,515

Adjustments to reconcile net income to net cash provided by operating activities:

Amortization of capitalized software costs

5,424

5,280

23,016

20,108

Amortization and write-off of debt issuance costs

127

494

508

1,026

Amortization of other intangibles

3,099

3,421

12,397

21,109

Change in fair value of contingent consideration

—

(1,442

)

7

(1,367

)

Deferred income taxes

180

(8,812

)

215

(8,854

)

Depreciation

1,496

1,909

6,902

7,997

Excess tax deficiency (benefit) from share-based compensation

(191

)

(72

)

643

798

Impairment of assets

2,329

3,324

3,906

5,539

Loss on disposal of equipment and improvements

20

(15

)

97

12

Non-cash operating lease costs

1,277

1,633

5,732

6,786

Provision for bad debts

773

790

1,915

2,834

Share-based compensation

7,867

5,947

26,552

22,710

Changes in assets and liabilities:

Accounts receivable

(6,750

)

(1,590

)

(431

)

(369

)

Contract assets

(824

)

(1,863

)

(5,610

)

(5,921

)

Accounts payable

(5,921

)

3,410

(2,329

)

615

Contract liabilities

6,401

4,208

8,417

(3,923

)

Accrued compensation and related benefits

6,717

10,372

(1,638

)

26,582

Income taxes

1,564

5,109

(5,650

)

1,615

Deferred compensation

(441

)

(4

)

610

1,320

Operating lease liabilities

(2,672

)

(6,693

)

(12,734

)

(16,736

)

Other assets and liabilities

(3,914

)

(2,286

)

(10,598

)

7,122

Net cash provided by operating activities

16,909

22,540

53,545

98,518

Cash flows from investing activities:

除了s to capitalized software costs

(7,663

)

(5,664

)

(25,500

)

(24,578

)

除了s to equipment and improvements

(545

)

(2,215

)

(2,582

)

(3,761

)

Acquisition related working capital adjustment payments

—

—

—

(206

)

Net cash used in investing activities

(8,208

)

(7,879

)

(28,082

)

(28,545

)

Cash flows from financing activities:

Proceeds from line of credit

—

—

—

50,000

Repayments on line of credit

—

(29,000

)

—

(179,000

)

支付的债务issuance costs

—

(1,423

)

—

(1,423

)

Payment of contingent consideration related to acquisitions

—

—

(540

)

—

Proceeds from issuance of shares under employee plans

4,137

1,482

5,014

3,479

Repurchase of common stock

—

—

(35,874

)

—

Payments for taxes related to net share settlement of equity awards

(441

)

(876

)

(5,891

)

(4,773

)

Net cash provided by (used in) financing activities

3,696

(29,817

)

(37,291

)

(131,717

)

Net increase (decrease) in cash, cash equivalents, and restricted cash

12,397

(15,156

)

(11,828

)

(61,744

)

Cash, cash equivalents, and restricted cash at beginning of period

54,350

93,731

78,575

140,319

Cash, cash equivalents, and restricted cash at end of period

$

66,747

$

78,575

$

66,747

$

78,575

NEXTGEN HEALTHCARE, INC.

SUPPLEMENTAL FINANCIAL INFORMATION

(In thousands)

The following table presents our revenues disaggregated by our major revenue categories and by occurrence:

Three Months
Ended March 31,

Fiscal Year
Ended March 31,

2022

2021

2022

2021

Recurring revenues:

Subscription services

$

42,055

$

38,218

$

162,636

$

148,403

Support and maintenance

39,887

38,419

155,623

152,956

Managed services

28,924

27,032

116,722

103,138

Electronic data interchange and data services

26,361

25,694

104,732

98,322

Total recurring revenues

137,227

129,363

539,713

502,819

Software, hardware, and other non-recurring revenues:

Software license and hardware

7,145

8,163

31,347

28,825

Other non-recurring services

6,887

6,662

25,290

25,177

Total software, hardware and other non-recurring revenues

14,032

14,825

56,637

54,002

Total revenues

$

151,259

$

144,188

$

596,350

$

556,821

Recurring revenues as a percentage of total revenues

90.7

%

89.7

%

90.5

%

90.3

%

NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

Three Months

Ended March 31,

Fiscal Year

Ended March 31,

2022

2021

2022

2021

Income before provision for income taxes - GAAP

$

2,273

$

(969

)

$

5,196

$

9,275

Non-GAAP adjustments:

Acquisition costs, net

—

(1,409

)

—

(1,029

)

Amortization of acquired intangible assets

3,099

3,421

12,397

21,109

Amortization of deferred debt issuance costs

127

494

508

1,026

Impairment of assets

2,329

3,324

3,906

5,539

Restructuring costs

—

—

539

2,562

Shareholder disputes and related costs, net of insurance

531

6,060

29,747

16,274

Share-based compensation

7,867

5,947

26,552

22,710

Other non-run-rate expenses*

107

620

4,486

4,754

Total adjustments to GAAP income before provision for income taxes:

14,060

18,457

78,135

72,945

Income before provision for income taxes - Non-GAAP

16,333

17,488

83,331

82,220

Provision for income taxes

3,266

3,498

16,666

16,444

Net income - Non-GAAP

$

13067年

$

13,990

$

66,665

$

65,776

Diluted net income per share - Non-GAAP

$

0.19

$

0.21

$

0.98

$

0.98

Weighted-average shares outstanding (diluted):

67,547

67,919

67,788

66,885

* Other non-run-rate expenses for the three months ended March 31, 2022consist of $107excess lease-related expense for vacated facilities.

Other non-run-rate expenses for the three months ended March 31, 2021consist primarily of $552excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan and $68of professional services costs not related to core operations.

Other non-run-rate expenses for the year ended March 31, 2022consist primarily of $1,242excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses, related to the restructuring plan and $2,707of executive transition costs, including severance and other costs related to the departure of the CEO, $498of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic, and $39of professional services costs not related to core operations.

Other non-run-rate expenses for the year ended March 31, 2021consist primarily of $3,183excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan, $1,472of professional services costs not related to core operations, and $99of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic.

RECONCILIATION OF FREE CASH FLOW

Three Months
Ended March 31,

Fiscal Year
Ended March 31,

2022

2021

2022

2021

Net cash provided by operating activities

$

16,909

$

22,540

$

53,545

$

98,518

除了s to capitalized software costs

(7,663

)

(5,664

)

(25,500

)

(24,578

)

除了s to equipment and improvements

(545

)

(2,215

)

(2,582

)

(3,761

)

Free cash flow

$

8,701

$

14,661

$

25,463

$

70,179

NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands)

RECONCILIATION OF ADJUSTED EBITDA

Three Months
Ended March 31,

Fiscal Year
Ended March 31,

2022

2021

2022

2021

Income (loss) from operations - GAAP

$

2,813

$

(290

)

$

6,658

$

12,817

Non-GAAP adjustments:

Acquisition costs, net

—

(1,409

)

—

(1,029

)

Amortization of acquired intangible assets

3,099

3,421

12,397

21,109

Impairment of assets

2,329

3,324

3,906

5,539

Restructuring costs

—

—

539

2,562

Shareholder disputes and related costs, net of insurance

531

6,060

29,747

16,274

Share-based compensation

7,867

5,947

26,552

22,710

Other non-run-rate expenses*

107

620

4,486

4,754

Total adjustments to GAAP income (loss) from operations:

13,933

17,963

77,627

71,919

Income from operations - Non-GAAP

16,746

17,673

84,285

84,736

Amortization of capitalized software costs

5,424

5,280

23,016

20,108

Depreciation

1,496

1,909

6,902

7,997

Depreciation and Amortization - Non-GAAP

6,920

7,189

29,918

28,105

Adjusted EBITDA - Non-GAAP

$

23,666

$

24,862

$

114,203

$

112,841

Total revenues

$

151,259

$

144,188

$

596,350

$

556,821

Adjusted EBITDA margin - Non-GAAP

15.6

%

17.2

%

19.2

%

20.3

%

* Other non-run-rate expenses for the three months ended March 31, 2022consist of $107excess lease-related expense for vacated facilities.

Other non-run-rate expenses for the three months ended March 31, 2021consist primarily of $552excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan and $68of professional services costs not related to core operations.

Other non-run-rate expenses for the year ended March 31, 2022consist primarily of $1,242excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses, related to the restructuring plan and $2,707of executive transition costs, including severance and other costs related to the departure of the CEO, $498of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic, and $39of professional services costs not related to core operations.

Other non-run-rate expenses for the year ended March 31, 2021consist primarily of $3,183excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan, $1,472of professional services costs not related to core operations, and $99of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic.

A reconciliation of adjusted EBITDA for each interim reporting period within the fiscal years ended March 31, 2022and 2021 may be accessed through our Investor Relations website athttp://investor.www.orderpulsa.com.

Media Relations Contact
Tami Andrade
(949) 237-6083
tandrade@www.orderpulsa.com

投资者关系联系
Matthew Scalo
(415) 370-9202
mscalo@www.orderpulsa.com

Source: NextGen Healthcare, Inc.